Tenax Therapeutics, Inc. Stock price

Equities

TENX

US88032L6056

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
3.87 USD +4.31% Intraday chart for Tenax Therapeutics, Inc. +0.52% -82.38%
Sales 2023 * - Sales 2024 * - Capitalization 6.83M
Net income 2023 * -7M Net income 2024 * -12M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.13 x
P/E ratio 2024 *
-0.61 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 16.5%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.31%
1 week+0.52%
Current month-15.69%
1 month-7.42%
3 months-83.49%
6 months-83.32%
Current year-82.38%
More quotes
1 week
3.48
Extreme 3.48
3.95
1 month
3.48
Extreme 3.48
5.17
Current year
3.48
Extreme 3.48
22.88
1 year
3.48
Extreme 3.48
61.20
3 years
3.48
Extreme 3.48
3 952.00
5 years
3.48
Extreme 3.48
5 888.00
10 years
3.48
Extreme 3.48
190 720.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 21-07-13
Director of Finance/CFO 69 Jan. 10
Chief Tech/Sci/R&D Officer 74 21-01-14
Members of the board TitleAgeSince
Chairman 65 14-04-03
Director/Board Member 67 21-02-24
Director/Board Member 72 21-02-24
More insiders
Date Price Change Volume
24-03-27 3.87 +4.31% 31,764
24-03-26 3.71 +0.27% 75,226
24-03-25 3.7 -3.14% 32,776
24-03-22 3.82 -2.55% 25,185
24-03-21 3.92 +1.82% 65,005

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). It has the rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.87 USD
Average target price
32.5 USD
Spread / Average Target
+739.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Tenax Therapeutics, Inc. - Nasdaq